Skip to main content
Explore URMC

Bradley M. Turner, M.D., M.P.H., M.H.A.

Contact Information

Phone Numbers

Office: (585) 341-6597

Office: (585) 275-2228

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting



Dr. Turner is board certified in Anatomic and Clinical Pathology, and in Family Medicine. Dr. Turner serves as a faculty member on the breast and gynecologic pathology subspecialty services in the Department of Pathology and Laboratory Medicine at URMC. He provides anatomic pathology services at both Highland Hospital and Strong Memorial Hospital, while also providing clinical pathology services at Highland Hospital. Dr. Turner also provides urgent care consultation services in Rochester New York.

Dr. Turner enjoys his role as a pathologist in the community and often relies on his experience as a family practitioner during his evaluation of cases. "The biggest difference, of course, is the decrease in patient care contact," he has been known to say. "But there's a unique dynamic I often feel with clinicians' as a result of my experience with patient care. The information I provide in a signed out report is grounded in the sincere appreciation of the conundrums that often occur in formulating diagnosis and treatment plans for the patient, including the emotional conflicts that often arise during this decision making process".

Dr. Turner and his wife, Dr. Stella King-Turner, an Associate Professor in the Departments of Emergency Medicine and Family Medicine at URMC, are parents of three children: twins Alyssa and Benjamin, age 13, and Colin, age 10. Dr. Turner also serves on the board of directors of the Anthony L. Jordan Health Corporation, as well as the Black Physicians Network of Greater Rochester, a 501(c)(3) not for profit organization with the vision of "Black physicians partnering with each other and the community to address disparities in healthcare and promote excellence and innovation in our youth." Brad is also very active in his fraternity Sigma Pi Phi, Gamma Iota Chapter. He enjoys music, sports, and reading in his spare time.

Dr. Turner's influences, like his professional assignments, are diverse. Among them: Dr. I-Tien Yeh, previously Director of the Core Pathology lab for the Cancer Research and Therapy Center at University of Texas Health Science Center at San Antonio, and Dr. Fattaneh Tavassoli, Professor of Pathology, Obstetrics, Gynecology, and Reproductive Sciences at Yale School of Medicine. Another is Dr. James Henry, a neuropathologist with a military background whom Dr. Turner said "commanded me to apply to Yale during a chance hallway conversation. He recognized potential in me - and told me. I will always be grateful to him for that. One's destiny can truly be affected by a chance hallway conversation."

And, one more influence: Benjamin Franklin, author of one of Dr. Turners favorite quotes--
"Tell me and I forget, teach me and I may remember, involve me and I learn."

Professional Background

After graduating from the Bronx High School of Science (Bronx NY) in 1981, Dr. Turner majored in chemistry and minored in math at Howard University (Washington DC). He subsequently completed his B.S. degree in Environmental Health Science at York College/City University of New York in 1992, after being honorably discharged from the United States Army Reserves. He was accepted into the University of Medicine and Dentistry/Robert Wood Johnson Medical (now Rutgers University Medical School) where he completed a combined MD/MPH degree in 1997, and in 2000 he completed a residency in family medicine at Duke/Southern Regional AHEC in Fayetteville, NC. He started practicing in Burgaw NC, subsequently moving to Sarasota FL, where he became a partner at a large multispecialty medical group over the next five years. He decided to return to residency in 2005 to study anatomic and clinical pathology.
Dr. Turner completed a residency at the University of Florida, College of Medicine (Gainesville) in 2009, while also finishing a second Master degree in Health Administration (MHA) at the University of South Florida, College of Public Health (Tampa). He subsequently completed fellowships in general surgical pathology at the University of Texas Health Science Center in San Antonio, TX (2010), oncologic surgical pathology at Roswell Park Cancer Institute in Buffalo, NY (2011), and breast and gynecologic pathology at Yale School of Medicine in New Haven, CT (2012).

Today, Dr. Turner serves as a faculty member on the breast and gynecologic pathology subspecialty services in the Department of Pathology and Laboratory Medicine at URMC. He provides anatomic pathology services at both Highland Hospital and Strong Memorial Hospital, while also providing clinical pathology services at Highland Hospital. Dr. Turner also continues to provide direct patient care services, providing urgent care consultation services in Rochester.

Dr. Turner has research interests in cancer biology and cancer outcomes, including pathologic and non-pathologic correlates of breast cancer outcomes, the role of the tumor microenvironment in breast cancer outcomes, and the role of health care disparities in breast cancer outcomes. He has authored or co-authored several recent publications including: Use of modified Magee equations and histologic criteria to predict the Oncotype DX® recurrence score (Mod Pathology, 2015); Pathologic Diagnosis, Immunohistochemistry, Multigene Assays and Breast Cancer Treatment: Progress toward 'Precision' Cancer Therapy (Biotechnic & Histochemistry, 2015); and, Nomograms to predict the likelihood of upgrade of Atypical Ductal Hyperplasia diagnosed on a core needle biopsy in mammographically detected lesions (Histopathology, 2014). He also stays active in the primary care literature, having recently authored a chapter with Dr. David Hicks on breast cancer in the popular family medicine text book Family Medicine: Principles and Practices, 7th edition (2016).


Increasing awareness of new prognostic and predictive methodologies, and the introduction of next generation sequencing, clearly has established the role of precision medicine in targeted therapy, particularly for cancer patients. Precision medicine includes combinations of diagnostic testing and treatment options that can be offered to patients at presentation, and potentially throughout the course of their disease as new mutations arise and response to treatment diminishes. Precision targeted therapy for breast cancer treatment remains a challenge, because breast cancer is a disease with significant nonbiologic and biologic diversity. The primary clinical goal in breast cancer treatment is to coordinate the most effective local, regional and systemic treatment regimens, including targeted drug regimens, for each patient. The traditional clinical-pathologic paradigm for risk stratification of patients with breast cancer is based on careful considerations of a combination of clinical and histopathologic factors including patient age, menopausal status, tumor size, histologic type, histologic grade, measures of proliferation, lymphovascular invasion, lymph node staging, and evidence of distant metastasis. Differences in histopathologic features of each breast cancer are related directly to the patients underlying tumor biology and risk for metastasis. The use of the biomarkers, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), have been invaluable for assessing patient suitability for hormonal or HER2 therapy, thus potentially decreasing a patients risk for recurrence and metastasis; however, the interpretation of these biomarkers is subjective, and the indications for adding chemotherapy are even more challenging. The introduction of multi-gene assays such as Oncotype DX®, and next generation sequencing, has increased our understanding of both tumor biology and clinical behavior, including risks for recurrence and metastasis. These newer technologies offer the possibility for considering more appropriate therapeutic choices, and challenge the relevance of the traditional clinical-pathologic paradigm for selecting the optimal management for a breast cancer patient; however, the cost of these newer technologies is a concern. Several studies have suggested that standard histopathologic variables can provide information similar to that provided by newer technologies, with less of a cost burden to the healthcare system. My work currently focuses on evaluating histologic variables which may provide cost-efficient and cost-effective prognostic and predictive outcome data for breast cancer patients. It has been reported that the tumor microenvironment may affect the Oncotype DX® recurrence score, which has been shown to be both prognostic and predictive of breast cancer recurrence in certain populations of breast cancer patients. In collaboration with Dr. Ed Brown at the University of Rochester (Rochester, NY), Dr. Turner is beginning to explore how components of the tumor microenvironment, such as the extracellular matrix (ECM), may be contributing to breast cancer recurrence and metastasis, and how quantitative analysis of components of the tumor microenvironment such as the ECM can reveal important insights into the process of breast tumor metastasis. In collaboration with Dr. Kate-Rittenhouse-Olson, Dr. Turner is also beginning to explore the value antibodies that potentially target cancer tissue using immunohistochemistry in "in-vivo" models.



  • Family Medicine - American Board of Family Medicine
  • Pathology, Anatomic Pathology and Clinical Pathology - American Board of Pathology


MD | New Jersey Dental School

MS | University Of South Florida College of Public Health

Post-doctoral Training & Residency

07/01/2011 - 06/30/2012
Fellowship in Pathology at Yale New Haven Hospital Temple Medical Center

07/01/2010 - 06/30/2011
Fellowship in Surgical Oncology at Roswell Park Cancer Institute-GME

07/01/2009 - 06/30/2010
Fellowship in Surgical Pathology at UT Health San Antonio Long School of Medicine

07/01/2005 - 06/30/2009
Residency in Pathology at University of Florida College of Medicine-GME

07/01/1998 - 06/30/2000
Residency in Family Medicine at Cape Fear Valley Medical Center/Health System

07/01/1997 - 06/30/1998
Internship in Family Medicine at Cape Fear Valley Medical Center/Health System

VIEW ALL expand_more


Journal Articles

Abu-Farsakh S, Drage MG, Huber AR, Turner BM, Varghese S, Wang X, Whitney-Miller CL, Gonzalez RS. "Interobserver Agreement in the Diagnosis of Anal Dysplasia: Comparison Between Gastrointestinal and Gynaecologic Pathologists and Utility of Consensus Conferences." Histopathology.. 2021 Oct 3; Epub 2021 Oct 03.

Moisini I, Zhang H, D'Aguiar M, Hicks DG, Turner BM. "L1CAM Expression in Recurrent Estrogen Positive/HER2 Negative Breast Cancer: A Novel Biomarker Worth Considering." Applied immunohistochemistry & molecular morphology : AIMM. 2021 Apr 1; 29(4):287-292.

Turner BM, Cramer SF, Heller DS. "The pathogenesis of abnormal uterine bleeding in myopathic uteri." Annals of diagnostic pathology.. 2021 Mar 2; 52:151726. Epub 2021 Mar 02.

Books & Chapters

Chapter Title: A 51-Year-Old Woman with a Breast Lump
Book Title: Pathology Case Reports: Beyond the Pearls
Author List: Turner BM
Edited By: Bhanote, Hicks
Published By: Elsevier 2021 in Philadelphia

Chapter Title: The histopathology of skeletal metastasis
Book Title: Bone Cancer: Bone Sarcomas and Bone Metastases - From Bench to Bedside
Author List: Turner BM, Hicks D
Published By: Elsevier 2021 in Philadelphia

Chapter Title: A 77-Year-Old Female Presenting with a Lesion in the Vaginal Area
Book Title: Pathology Case Reports: Beyond the Pearls
Author List: Turner BM
Edited By: Bhanote, Hicks
Published By: Elsevier 2021 in Philadelphia